GRETCHEN LOCKARD: Open Payments
NPI 1023069796 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,907 in 115 payments from 26 companies in 2025. Trend: 2023 $1,967 · 2024 $2,290 · 2025 $1,907
Food & beverage: $1,907
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 22 | $295 |
| AstraZeneca Pharmaceuticals LP | 3 | $193 |
| GlaxoSmithKline, LLC. | 6 | $176 |
| Novo Nordisk Inc | 12 | $174 |
| ABBVIE INC. | 13 | $171 |
| Lilly USA, LLC | 11 | $171 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $160 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $96 |
| Phathom Pharmaceuticals, Inc. | 5 | $74 |
| Abbott Laboratories | 3 | $64 |
Products named: AIRSUPRA, XIFAXAN, AREXVY, NURTEC ODT, JARDIANCE, MOUNJARO, Ozempic, UBRELVY.
Industry payments across VA — which companies pay providers there.
